E Fund Management Co. Ltd. Buys 1,219 Shares of Novavax, Inc. (NASDAQ:NVAX)

E Fund Management Co. Ltd. increased its stake in shares of Novavax, Inc. (NASDAQ:NVAX) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,340 shares of the biopharmaceutical company’s stock after acquiring an additional 1,219 shares during the period. E Fund Management Co. Ltd.’s holdings in Novavax were worth $204,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. State Street Corp increased its holdings in Novavax by 26.7% during the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after purchasing an additional 1,621,772 shares in the last quarter. Shah Capital Management grew its holdings in shares of Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after buying an additional 1,333,305 shares in the last quarter. Two Sigma Advisers LP raised its position in Novavax by 48.9% in the 3rd quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after buying an additional 656,900 shares during the last quarter. Bank of Montreal Can raised its position in Novavax by 26.7% in the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after buying an additional 517,727 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Novavax by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock worth $44,245,000 after acquiring an additional 304,159 shares during the last quarter. 53.04% of the stock is owned by institutional investors.

Novavax Price Performance

Shares of NVAX stock opened at $8.34 on Monday. The company has a fifty day moving average price of $8.46 and a two-hundred day moving average price of $9.77. Novavax, Inc. has a one year low of $3.81 and a one year high of $23.86. The stock has a market cap of $1.34 billion, a P/E ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter last year, the business posted ($1.44) earnings per share. As a group, equities research analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NVAX. BTIG Research started coverage on shares of Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 price objective on the stock. TD Cowen upgraded shares of Novavax to a “hold” rating in a research note on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $18.00.

Insider Transactions at Novavax

In other Novavax news, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares of the company’s stock, valued at $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares in the company, valued at approximately $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 14,150 shares of company stock worth $119,641. 1.00% of the stock is owned by company insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.